Docetaxel as Second-line Monotherapy for Advanced Non-small Cell Lung Cancer / 결핵및호흡기질환
Tuberculosis and Respiratory Diseases
;
: 465-472, 2005.
Artigo
em Coreano
| WPRIM
| ID: wpr-9030
ABSTRACT
BACKGROUND:
The survival benefit associated with first-line chemotherapy in lung cancer has led to the need for second-line chemotherapy, for which Docetaxel (Taxotere(R)) has proven efficacy in both settings. This study evaluated the safety and efficacy of docetaxel in patients with non-small cell lung cancer who had failed first-line platinum- based chemotherapy.METHODS:
Thirty one patients with non-small-cell lung cancer, who had failed first-line platinum-based chemotherapy, between March 1999 and August 2003, were enrolled in this study. Patients received intravenous docetaxel, either 75 mg/m2 or 100 mg/m2, with routine premedication every three weeks.RESULTS:
Fourteen patients (45.2%) had a partial response. The median survival and progression-free survival times were 12.5 months (95% CI 7.3-17.6) and 3.0 months (95% CI 1.6-4.5), respectively. This study showed 2 factors gave different survival benefits; the age ( or = 60 years 6.6 months, p = 0.0105) and the histological type (adenocarcinoma 25.6 months vs. others 7.9 months, p=0.0055). The predominant toxicity was neutropenia, which occurred as WHO grade 3 or 4 in 38.7 % of patients. One treatment-related death was also reported. Non-hematological toxicity was minor and easily controlled. There were no significant statistical differences in the survival benefit and toxicity between the two doses.CONCLUSION:
Docetaxel, as second-line monotherapy, was well tolerated and effective in patients with non-small- cell lung cancer who failed first-line platinum-based chemotherapy.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Pré-Medicação
/
Carcinoma Pulmonar de Células não Pequenas
/
Intervalo Livre de Doença
/
Tratamento Farmacológico
/
Neoplasias Pulmonares
/
Neutropenia
Limite:
Humanos
Idioma:
Coreano
Revista:
Tuberculosis and Respiratory Diseases
Ano de publicação:
2005
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS